Tesaro — Q2 2014 Earnings Presentation
17 slides from Tesaro's earnings presentation, Jul 24, 2014
Slide 1: Second-Quarter Results July 24, 2014
Second-Quarter Results July 24, 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,
Slide 3: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 4: A Balanced Portfolio of Product Candidates
CINV: Chemotherapy-induced nausea & vomiting A/C: anthracycline/cyclophosphamide. MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy. NSCLC: Non-small cell lung cancer. * In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration. A Balanced Portfol
Slide 5: Tim Pearson, Chief Financial Officer
Tim Pearson Chief Financial Officer
Slide 6: Q2 2014 Financial Results
Q2 2014 Financial Results Three Months Ended June 30, 2014 Three Months Ended June 30, 2013 Expenses: Research & Development $30,569 $18,177 General & Administrative 5,587 3,412 Acquired In-process R&D 900 - Total Expenses 37,056 21,589 Loss from Operations (37,056) (21,589) Interest Income 5 25 Net
Slide 7: Mary Lynne Hedley, Ph.D., President
Mary Lynne Hedley, Ph.D. President
Slide 8: Development Programs Update
NDA: New drug application IV: Intravenous SCLC: Small cell lung cancer IND: Investigational new drug application Development Programs Update Each of three pivotal trials successfully achieved its primary endpoint Data was presented at ASCO & MASCC meetings Pre-NDA meeting held; oral NDA on track for
Slide 9: Development Programs Update
NDA: New drug application IV: Intravenous SCLC: Small cell lung cancer IND: Investigational new drug application Development Programs Update Each of three pivotal trials successfully achieved its primary endpoint Data was presented at ASCO & MASCC meetings Pre-NDA meeting held; oral NDA on track for
Slide 10: Development Programs Update
NDA: New drug application IV: Intravenous SCLC: Small cell lung cancer IND: Investigational new drug application Development Programs Update Each of three pivotal trials successfully achieved its primary endpoint Data was presented at ASCO & MASCC meetings Pre-NDA meeting held; oral NDA on track for
Slide 11: Development Programs Update
NDA: New drug application IV: Intravenous SCLC: Small cell lung cancer IND: Investigational new drug application Development Programs Update Each of three pivotal trials successfully achieved its primary endpoint Data was presented at ASCO & MASCC meetings Pre-NDA meeting held; oral NDA on track for
Slide 12: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 13: Commercial Organization: Hiring Targeted for Late in NDA Review Process
Commercial Organization: Hiring Targeted for Late in NDA Review Process Approximately 120 Total Headcount Opportunity for Significant Leverage: Anticipate Rolapitant P&L to Break Even at Annual Sales of ~$50-60M NDA: New Drug Application
Slide 14: TESARO Is Positioned for Success
CINV: chemotherapy-induced nausea & vomiting ALKi: ALK inhibitor IO: Immuno-oncology KOL: Key opinion leader Market opportunity projections are based upon Company estimates TESARO Is Positioned for Success Cash and equivalents of ~$151M as of 6/30/2014 Well Capitalized Commercial, development and re
Slide 15: Q&A
Q&A W TESARO
Slide 16: 2H 2014 Key Priorities
Submit NDA for oral rolapitant to the U.S. FDA Advance IV rolapitant clinical program Continue to advance niraparib Phase 3 NOVA and BRAVO trials Expand the niraparib clinical development program and continue enrolling the combination study in Ewing’s sarcoma Continue to evaluate activity of TSR-011
Slide 17: Second-Quarter Results July 24, 2014
Second-Quarter Results July 24, 2014